Phase III Avelumab Trial Discontinued in Frontline Ovarian Cancer
The ongoing phase III JAVELIN Ovarian PARP 100 study, which was evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance avelumab in combination with talazoparib in patients with locally advanced or metastatic ovarian cancer, has been discontinued.
Source: OncLive